=== Intervention Extract 1 (Intervention) ===
Oxf
5 (Oxf
ndlagen der
nzgrad
ford 2009)
ford 2011)
ford 2011)
ford 2011)
ford 2011)
ford 2011)
© L
Methodik 29
Beschreibung
) Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
appraisal, or based on physiology, bench research or “first principles”
) Category - Does this intervention help? (Treatment Benefits): Systematic re-
view of randomized trials or n-of-1 trials
) Category - Does this intervention help? (Treatment Benefits): Randomized
trial or observational study with dramatic effect
) Category - Does this intervention help? (Treatment Benefits): Non-random-
ized control

=== Intervention Extract 2 (Intervention) ===
ng
) Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
appraisal, or based on physiology, bench research or “first principles”
) Category - Does this intervention help? (Treatment Benefits): Systematic re-
view of randomized trials or n-of-1 trials
) Category - Does this intervention help? (Treatment Benefits): Randomized
trial or observational study with dramatic effect
) Category - Does this intervention help? (Treatment Benefits): Non-random-
ized controlled cohort/follow-up study (a systematic review is generally bet-
ter than an individual study)
) Category - Does this int

=== Intervention Extract 3 (Intervention) ===
esearch or “first principles”
) Category - Does this intervention help? (Treatment Benefits): Systematic re-
view of randomized trials or n-of-1 trials
) Category - Does this intervention help? (Treatment Benefits): Randomized
trial or observational study with dramatic effect
) Category - Does this intervention help? (Treatment Benefits): Non-random-
ized controlled cohort/follow-up study (a systematic review is generally bet-
ter than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Case-series,
case-control studies, or historically controlled studies (a systematic rev

=== Intervention Extract 4 (Intervention) ===
ion help? (Treatment Benefits): Randomized
trial or observational study with dramatic effect
) Category - Does this intervention help? (Treatment Benefits): Non-random-
ized controlled cohort/follow-up study (a systematic review is generally bet-
ter than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Case-series,
case-control studies, or historically controlled studies (a systematic review is
generally better than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Mechanism-
based reasoning
Hohe Qualität der Evidenz nach GRADE = Wir

=== Intervention Extract 5 (Intervention) ===
study (a systematic review is generally bet-
ter than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Case-series,
case-control studies, or historically controlled studies (a systematic review is
generally better than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Mechanism-
based reasoning
Hohe Qualität der Evidenz nach GRADE = Wir sind sehr sicher, dass der
wahre Effekt nahe bei dem Effektschätzer liegt.
Moderate Qualität nach GRADE = Wir haben mäßig viel Vertrauen in den Ef-
fektschätzer: Der wahre Effekt ist wahrscheinlich nah

=== Intervention Extract 6 (Intervention) ===
von 55 auf 50 Jahre als auch die
kumulative Mindest-Tabakrauchexposition von 30 auf 20 Packungsjahre [149]. Neben
den beiden größten randomisierten Studien von NLST [158] und NELSON [178] stam-
men zusätzliche Beweise für die USPSTF-Empfehlung 2021aus quantitativen Modellie-
rungsstudien im Cancer Intervention and Surveillance Modeling Network (CISNET).
Diese zeigten, dass das Screening von Personen im Alter von 50–80 Jahren mit 20 Pa-
ckungsjahren oder mehr aktivem Rauchen voraussichtlich zu mehr Nutzen führt bei
akzeptablem Anstieg der erwarteten finanziellen Kosten und Nebenwirkungen des
Screenings, i

=== Intervention Extract 7 (Intervention) ===
t beeinflussen, gehören die
Methode zur Auswahl der in Frage kommenden Population, die Teilnahmerate, das
Intervall zwischen den Screeningrunden, die Methode des Lungenrundherdmanage-
ments, der Ansatz für die klinische Aufarbeitung der Niedrigdosis-CT-Befunde sowie
die Integration einer Rauchstopp-Intervention bzw. eines zertifizierten Rauchfreipro-
gramms [215].
Stand Implementierung von Niedrigdosis-CT-Lungenkrebsscreening
Internationaler Implementierungsstatus
Außerhalb von Deutschland wurden nationale Niedrigdosis-CT Lungenkrebs-Scree-
ningprogramme nach den USA bereits in Australien, Großbritannien,

=== Intervention Extract 8 (Intervention) ===
6]. Rund 35–55% der Teilnehmer in
den randomisierten Low-Dose-CT-Screeningstudien bzw. Pilotstudien waren aktive
Raucher [227], [178], [228]. Ein Rauchstopp senkt ebenso wie ein Niedrigdosis-CT-
Lungenkrebs-Screening-Programm die lungenkrebsbedingte Mortalität. Bereits eine
einmalige therapeutische Intervention zur Tabakentwöhnung ist effektiv und redu-
ziert nicht nur die lungenkrebsbedingte Mortalität, sondern auch die Sterblichkeit an-
derer prävalenter tabakassoziierter Erkrankungen. Bei Kombination beider Verfahren
addieren sich deren mortalitätssenkende Effekte. Gleichzeitig wurden bei aktiven Rau-

=== Intervention Extract 9 (Intervention) ===
ienen CT-Verlaufs-
kontrollen bei subsoliden Lungenherden dazu, den optimalen Zeitpunkt für eine Inter-
vention zu identifizieren bzw. eine im Kontext der Gesamtmorbidität des Patienten
4 Inzid
dentell
ler Lungenrundherd (außerhalb eines Programms zur Lungenkrebs-Früherkennung) 145
nicht hilfreiche Intervention komplett zu vermeiden. Denn auch bei bereits bestehen-
der Malignität ist die Wachstumsgeschwindigkeit subsolider Lungenrundherde typi-
scherweise außerordentlich gering, mit einer Größenkonstanz und fehlender Progres-
sion oft über mehrere Jahre. Entsprechend lang (3 – 5 Jahre) sollte die Dauer de

=== Intervention Extract 10 (Intervention) ===
it
einem Lungenkarzinom konnten im Rahmen einer systematischen Recherche der Leit-
liniengruppe vier prospektive, randomisierte Studien identifiziert werden [564], [568],
[607], [609] (siehe Tabelle 31).
e 31: Studienübersicht zur frühzeitigen Integration von Palliativversorgung
e Studienpopulation Intervention/ Kontrolle Ergebnisse
H., et Fallzahl: N=39 Intervention(s): Sign. Reduktion von De-
014 pressiviät und Ängstlich-
Setting: USA, single Manual with six items:
keit nach Wochen (gemes-
, center, home based
Content: strategies for sen mit (Patient Reported
care
balancing autonomy with Outcomes Measur

=== Intervention Extract 11 (Intervention) ===
schen Recherche der Leit-
liniengruppe vier prospektive, randomisierte Studien identifiziert werden [564], [568],
[607], [609] (siehe Tabelle 31).
e 31: Studienübersicht zur frühzeitigen Integration von Palliativversorgung
e Studienpopulation Intervention/ Kontrolle Ergebnisse
H., et Fallzahl: N=39 Intervention(s): Sign. Reduktion von De-
014 pressiviät und Ängstlich-
Setting: USA, single Manual with six items:
keit nach Wochen (gemes-
, center, home based
Content: strategies for sen mit (Patient Reported
care
balancing autonomy with Outcomes Measurement In-
Patientencharakteris- soliciting/accepting sup-

=== Intervention Extract 12 (Intervention) ===
needs, and support- 1.8; < .0001
kaukasisch ing/acknowledging the
Ängstlichkeit
caregiver.
SCLC (5): 16
12.35/14.84; SMD=-1.3;
6 weekly 60-minute tele-
NSCLC (Stage 3-4) (%): <.0001>
phone counselling ses-
sions with a trained inter-
ventionist
Kontrolle
Usual palliative care
as, M. Fallzahl: N=161 Intervention(s): Mittleres Überleben 14/8,5
2009 mo
Setting: USA, 2 sites Advanced practice nurses
, with palliative care spe- Gesamtüberleben
Patientencharakteris-
cialty training conducted 30,4/26,1 mo
tika: 62% männlich, Al-
4 initial structures educa-
ter im Mittel: 65 Jahre, mittleres follow up 10,7
tional

=== Intervention Extract 13 (Intervention) ===
v-
98% kaukasisch mo
ing sessions
married or living with Biasrisiko:
Manual for:
partner: 73%
1) problem solving unvollständige outcome-
lung: 34% 2) communication and Daten
social support
3) symptom management
4) advanced care plan-
ning and unfinished busi-
ness
Kontrolle Studie Studienpopulation Intervention/ Kontrolle Ergebnisse
Usual palliative care
Temel, J.S. Fallzahl: N=77 Intervention(s) QoL(tFAC-L)
et al., 2010 98,0/91,5/59/53,21/19
Setting: USA, single Early palliative care,
[564], center monthly, with palliative Gesamtmortalität
care team
Patientencharakteris- 12,9/22,9 %
tika: 55% weiblich, A

=== Intervention Extract 14 (Intervention) ===
tner: 73%
1) problem solving unvollständige outcome-
lung: 34% 2) communication and Daten
social support
3) symptom management
4) advanced care plan-
ning and unfinished busi-
ness
Kontrolle Studie Studienpopulation Intervention/ Kontrolle Ergebnisse
Usual palliative care
Temel, J.S. Fallzahl: N=77 Intervention(s) QoL(tFAC-L)
et al., 2010 98,0/91,5/59/53,21/19
Setting: USA, single Early palliative care,
[564], center monthly, with palliative Gesamtmortalität
care team
Patientencharakteris- 12,9/22,9 %
tika: 55% weiblich, Alter routine oncology care
Biasrisiko:
im Mittel: 64 Jahre, 95%
Kontrolle
kaukasisch

=== Intervention Extract 15 (Intervention) ===
with palliative Gesamtmortalität
care team
Patientencharakteris- 12,9/22,9 %
tika: 55% weiblich, Alter routine oncology care
Biasrisiko:
im Mittel: 64 Jahre, 95%
Kontrolle
kaukasisch
standard palliative care
ECOG 0 41%
and routine oncology
ECOG 1 47% care
Hirnmetastasen: 26%
Zimmer- Fallzahl: N=461 Intervention(s) Kein sign. Unterschied in
mann, C. et der LQ
Setting: Canada, single Early palliative care inter-
al., 2014
center, 16 medical on- vention with pc physician weitere Studien notwendig
[609], cologists, 24 clinics and nurse zur richtigen Patientenaus-
wahl für die Intervention
Patientencharakteris

=== Intervention Extract 16 (Intervention) ===
mer- Fallzahl: N=461 Intervention(s) Kein sign. Unterschied in
mann, C. et der LQ
Setting: Canada, single Early palliative care inter-
al., 2014
center, 16 medical on- vention with pc physician weitere Studien notwendig
[609], cologists, 24 clinics and nurse zur richtigen Patientenaus-
wahl für die Intervention
Patientencharakteris- once monthly, more often
tika: 74% weiblich, Alter necessary Biasrisiko: keine komplette
im Mittel: 68 Jahre, 85% Verblindung möglich, nur
Content:
kaukasisch ein Zentrum
Kontrolle
usual cancer care
Inzwischen liegen mehr Studien vor und im Jahr 2017 zeigten zwei Metaanalysen

=== Intervention Extract 17 (Intervention) ===
waren Einsatz einer Kom-
binationschemotherapie und Einsatz von Cisplatin und/oder Taxan sowie ein guter
Performance-Status (ECOG 0,1), Oligometastasierung, Hämoglobin > 11 g/dl, Alter < Auch unter einer laufenden Therapie müssen regelmäßige Kontrollen erfolgen, um
eine akute Symptomatik, die einer Intervention (bronchologische Intervention; pallia-
tive Radiotherapie; palliative Operation) bedarf, frühzeitig zu erkennen. Für alle Pati-
enten mit Lungenkarzinomen muss der Zugang zu den oben genannten Techniken
und Verfahren zeitnah gewährleistet sein.
8.6.2.2 Systemtherapie (Zweitlinie) bei Patienten mit

=== Intervention Extract 18 (Intervention) ===
ionschemotherapie und Einsatz von Cisplatin und/oder Taxan sowie ein guter
Performance-Status (ECOG 0,1), Oligometastasierung, Hämoglobin > 11 g/dl, Alter < Auch unter einer laufenden Therapie müssen regelmäßige Kontrollen erfolgen, um
eine akute Symptomatik, die einer Intervention (bronchologische Intervention; pallia-
tive Radiotherapie; palliative Operation) bedarf, frühzeitig zu erkennen. Für alle Pati-
enten mit Lungenkarzinomen muss der Zugang zu den oben genannten Techniken
und Verfahren zeitnah gewährleistet sein.
8.6.2.2 Systemtherapie (Zweitlinie) bei Patienten mit Plattenepithelkarzinom
ohne th

=== Intervention Extract 19 (Intervention) ===
Hä-
moptoe zunächst die Offenhaltung der zentralen Atemwege und die Oxygenierung im
Vordergrund. Die Intubation und Blockung eines kontralateralen Hauptbronchus ist
effektiv, um die nicht blutende Lunge zu schützen. Dabei erleichtern großlumige Tu-
ben die Bronchialtoilette und die bronchoskopische Intervention.
Die wichtigste diagnostische Maßnahme ist die Bronchoskopie. Zur Blutungslokalisa-
tion oder zum Staging kann darüber hinaus ein CT des Thorax notwendig werden
[1526](Evidenzgrad 1c).
Therapie
Die Bronchoskopie dient diagnostisch der Identifikation der Blutungsquelle und thera-
peutisch der Entfer

=== Intervention Extract 20 (Intervention) ===
• Tumortherapie induzierte Nausea und Emesis
• Tumortherapie induzierte Diarrhoe
• Orale Mucositis durch systemische Tumortherapie
• Tumortherapie induzierte Hauttoxizität
• Neurotoxizität – Chemotherapie induzierte periphere Neuropa
• Ossäre Komplikationen
o Ossäre Manifestationen
o Medikamentöse Intervention
o Chirurgische Intervention
o Strahlentherapeutische Intervention
o Radionuklidtherapie
o Therapie assoziierte Osteoporose
• Paravasate
• Supportive Maßnahmen in der Radioonkologie
• Radiogene Enteropathie/ Enteritis
• Chronische Enteropathie/ Enteritis- Therapie der chronischen D
• Radiogene Prokt

=== Intervention Extract 21 (Intervention) ===
Nausea und Emesis
• Tumortherapie induzierte Diarrhoe
• Orale Mucositis durch systemische Tumortherapie
• Tumortherapie induzierte Hauttoxizität
• Neurotoxizität – Chemotherapie induzierte periphere Neuropa
• Ossäre Komplikationen
o Ossäre Manifestationen
o Medikamentöse Intervention
o Chirurgische Intervention
o Strahlentherapeutische Intervention
o Radionuklidtherapie
o Therapie assoziierte Osteoporose
• Paravasate
• Supportive Maßnahmen in der Radioonkologie
• Radiogene Enteropathie/ Enteritis
• Chronische Enteropathie/ Enteritis- Therapie der chronischen D
• Radiogene Proktitis
• Späte radiogene Prokt

=== Intervention Extract 22 (Intervention) ===
zierte Diarrhoe
• Orale Mucositis durch systemische Tumortherapie
• Tumortherapie induzierte Hauttoxizität
• Neurotoxizität – Chemotherapie induzierte periphere Neuropa
• Ossäre Komplikationen
o Ossäre Manifestationen
o Medikamentöse Intervention
o Chirurgische Intervention
o Strahlentherapeutische Intervention
o Radionuklidtherapie
o Therapie assoziierte Osteoporose
• Paravasate
• Supportive Maßnahmen in der Radioonkologie
• Radiogene Enteropathie/ Enteritis
• Chronische Enteropathie/ Enteritis- Therapie der chronischen D
• Radiogene Proktitis
• Späte radiogene Proktitis
• Radiodermatitis
• Osteoradionek

=== Intervention Extract 23 (Intervention) ===
beim NSCLC ist noch
nicht identifiziert worden. Für die Zukunft sind randomisierte, kontrollierte Studien
wünschenswert, die nicht nur die klinische Effektivität und die Kosteneffektivität der
verschiedenen Nachsorgeprotokolle erfassen sollten, sondern auch die Lebensqualität
der Patienten je nach Intervention.
16 Nachsorge/
EK
Empfehlungsg
A/B
Level of Eviden Empfehlungsg
A
Level of Eviden /Verlauf/Follow-Up
Konsensbasierte Empfehlung geprüft 2025
Bei Patienten nach ablativer lokaler Therapie (Operation im Stadium I-II und III,
Strahlentherapie/ Strahlenchemotherapie im Stadium I und II) sollten die pos

=== Intervention Extract 24 (Intervention) ===
Row 9: 
Row 10: 
Row 11: 
Row 12: 
Row 13: 
Row 14: 
Row 15: 
Row 16: 
Row 17: 
Row 18: 
Row 19: 
Row 20: 
Row 21: 
Row 22: 
Row 23: 
Row 24: 
Row 25: 
Row 26:  Row 1: Abkür-|Erläuterung
Row 2: zung|
Row 3: |
Row 4: LoE|Level of Evidence
Row 5: LR|Lokalrezidiv
Row 6: LUSI|Lung tumor screening and intervention trial
Row 7: MASCC|Multinational Association of Supportive Care in Cancer
Row 8: MIA|melanoma inhibitory activity
Row 9: MRT|Magnetresonanztomographie
Row 10: Nab|nanoparticle albumin bound
Row 11: NCCN|National Comprehensive Cancer Network
Row 12: NCCTG|North Central Cancer Treatment Group
Row 13:

=== Intervention Extract 25 (Intervention) ===
d case-control studies)
Row 20: | Row 1: Evidenzgrad|Beschreibung
Row 2: 5 (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: 1 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: 2 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: 3 (Oxford 2011)|Category

=== Intervention Extract 26 (Intervention) ===
itical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: 1 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: 2 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: 3 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13:

=== Intervention Extract 27 (Intervention) ===
ment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: 2 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: 3 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individual study)
Row 15: 4 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control st

=== Intervention Extract 28 (Intervention) ===
tic effect
Row 10: |
Row 11: 3 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individual study)
Row 15: 4 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controlled studies (a systematic review is
Row 17: |
Row 18: |generally better than an individual study)
Row 19: 5 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Mechanism-
Row 20: |

=== Intervention Extract 29 (Intervention) ===
dy)
Row 15: 4 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controlled studies (a systematic review is
Row 17: |
Row 18: |generally better than an individual study)
Row 19: 5 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Mechanism-
Row 20: |based reasoning
Row 21: |
Row 22: ⊕⊕⊕⊕|Hohe Qualität der Evidenz nach GRADE = Wir sind sehr sicher, dass der
Row 23: |wahre Effekt nahe bei dem Effektschätzer liegt.
Row 24: |
Row 25: ⊕⊕⊕⊝|Moderate Qualität nach GRADE = Wir haben mäßig viel Vertrauen

=== Intervention Extract 30 (Intervention) ===
⊕⊕
Row 15: 
Row 16: ⊕⊝
Row 17: 
Row 18: ⊝⊝
Row 19: 
Row 20: ⊝⊝
Row 21:  Row 1: |Beschreibung
Row 2: )|Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: )|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: )|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: )|Category - Does this intervention he

=== Intervention Extract 31 (Intervention) ===
opinion without explicit critical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: )|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: )|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: )|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |te

=== Intervention Extract 32 (Intervention) ===
is intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: )|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: )|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individual study)
Row 15: )|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or hist

=== Intervention Extract 33 (Intervention) ===
servational study with dramatic effect
Row 10: |
Row 11: )|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individual study)
Row 15: )|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controlled studies (a systematic review is
Row 17: |
Row 18: |generally better than an individual study)
Row 19: )|Category - Does this intervention help? (Treatment Benefits): Mechanism-
Row 20: |based reasonin

=== Intervention Extract 34 (Intervention) ===
|ter than an individual study)
Row 15: )|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controlled studies (a systematic review is
Row 17: |
Row 18: |generally better than an individual study)
Row 19: )|Category - Does this intervention help? (Treatment Benefits): Mechanism-
Row 20: |based reasoning
Row 21: |
Row 22: |Hohe Qualität der Evidenz nach GRADE = Wir sind sehr sicher, dass der
Row 23: |wahre Effekt nahe bei dem Effektschätzer liegt.
Row 24: |
Row 25: |Moderate Qualität nach GRADE = Wir haben mäßig viel Vertrauen in den E

=== Intervention Extract 35 (Intervention) ===
bei Patienten|
Row 3: |mit einer nicht-heilbaren Lungenkarzinomerkrankung integriert werden (z.B.|
Row 4: |durch Beteiligung an interdisziplinäre Tumorkonferenzen oder durch einen pallia-|
Row 5: ||
Row 6: |tivmedizinischen Konsildienst).|
Row 7: |Konsens|
Row 8: || Row 1: Studie|Studienpopulation|Intervention/ Kontrolle|Ergebnisse
Row 2: Badr, H., et|Fallzahl: N=39|Intervention(s):|Sign. Reduktion von De-
Row 3: al., 2014|||pressiviät und Ängstlich-
Row 4: |Setting: USA, single|Manual with six items:|
Row 5: |||keit nach Wochen (gemes-
Row 6: [607],|center, home based||
Row 7: |care|Content: strategies

=== Intervention Extract 36 (Intervention) ===
kung integriert werden (z.B.|
Row 4: |durch Beteiligung an interdisziplinäre Tumorkonferenzen oder durch einen pallia-|
Row 5: ||
Row 6: |tivmedizinischen Konsildienst).|
Row 7: |Konsens|
Row 8: || Row 1: Studie|Studienpopulation|Intervention/ Kontrolle|Ergebnisse
Row 2: Badr, H., et|Fallzahl: N=39|Intervention(s):|Sign. Reduktion von De-
Row 3: al., 2014|||pressiviät und Ängstlich-
Row 4: |Setting: USA, single|Manual with six items:|
Row 5: |||keit nach Wochen (gemes-
Row 6: [607],|center, home based||
Row 7: |care|Content: strategies for|sen mit (Patient Reported
Row 8: ||balancing autonomy with|Outcome

=== Intervention Extract 37 (Intervention) ===
|12.35/14.84; SMD=-1.3;
Row 17: ||6 weekly 60-minute tele-|
Row 18: |NSCLC (Stage 3-4) (%):||<.0001>
Row 19: ||phone counselling ses-|
Row 20: |84||
Row 21: ||sions with a trained inter-|
Row 22: ||ventionist|
Row 23: ||Kontrolle|
Row 24: ||Usual palliative care|
Row 25: Bakitas, M.|Fallzahl: N=161|Intervention(s):|Mittleres Überleben 14/8,5
Row 26: et al., 2009|||mo
Row 27: |Setting: USA, 2 sites|Advanced practice nurses|
Row 28: [568],||with palliative care spe-|Gesamtüberleben
Row 29: |Patientencharakteris-||
Row 30: ||cialty training conducted|30,4/26,1 mo
Row 31: |tika: 62% männlich, Al-||
Row 32: ||

=== Intervention Extract 38 (Intervention) ===
ort|
Row 43: |||
Row 44: ||3) symptom management|
Row 45: ||4) advanced care plan-|
Row 46: ||ning and unfinished busi-|
Row 47: ||ness|
Row 48: ||Kontrolle| Row 1: Studie
Row 2: Badr,
Row 3: al., 20
Row 4: [607],
Row 5: 
Row 6: Bakita
Row 7: et al.,
Row 8: [568],
Row 9:  Row 1: e|Studienpopulation|Intervention/ Kontrolle|Ergebnisse
Row 2: H., et|Fallzahl: N=39|Intervention(s):|Sign. Reduktion von De-
Row 3: 014|||pressiviät und Ängstlich-
Row 4: |Setting: USA, single|Manual with six items:|
Row 5: |||keit nach Wochen (gemes-
Row 6: ,|center, home based||
Row 7: ||Content: strategies for|sen mit (Patient

=== Intervention Extract 39 (Intervention) ===
dvanced care plan-|
Row 46: ||ning and unfinished busi-|
Row 47: ||ness|
Row 48: ||Kontrolle| Row 1: Studie
Row 2: Badr,
Row 3: al., 20
Row 4: [607],
Row 5: 
Row 6: Bakita
Row 7: et al.,
Row 8: [568],
Row 9:  Row 1: e|Studienpopulation|Intervention/ Kontrolle|Ergebnisse
Row 2: H., et|Fallzahl: N=39|Intervention(s):|Sign. Reduktion von De-
Row 3: 014|||pressiviät und Ängstlich-
Row 4: |Setting: USA, single|Manual with six items:|
Row 5: |||keit nach Wochen (gemes-
Row 6: ,|center, home based||
Row 7: ||Content: strategies for|sen mit (Patient Reported
Row 8: |care||
Row 9: ||balancing autonomy with|Outcome

=== Intervention Extract 40 (Intervention) ===
7: |||12.35/14.84; SMD=-1.3;
Row 18: ||6 weekly 60-minute tele-|
Row 19: |NSCLC (Stage 3-4) (%):||<.0001>
Row 20: ||phone counselling ses-|
Row 21: |84||
Row 22: ||sions with a trained inter-|
Row 23: ||ventionist|
Row 24: ||Kontrolle|
Row 25: ||Usual palliative care|
Row 26: as, M.|Fallzahl: N=161|Intervention(s):|Mittleres Überleben 14/8,5
Row 27: 2009|||mo
Row 28: |Setting: USA, 2 sites|Advanced practice nurses|
Row 29: ,||with palliative care spe-|Gesamtüberleben
Row 30: |Patientencharakteris-||
Row 31: ||cialty training conducted|30,4/26,1 mo
Row 32: |tika: 62% männlich, Al-||
Row 33: ||4 initial str

=== Intervention Extract 41 (Intervention) ===
1) problem solving|unvollständige outcome-
Row 42: |lung: 34%|2) communication and|Daten
Row 43: ||social support|
Row 44: |||
Row 45: ||3) symptom management|
Row 46: ||4) advanced care plan-|
Row 47: ||ning and unfinished busi-|
Row 48: ||ness|
Row 49: ||Kontrolle| Row 1: Studie|Studienpopulation|Intervention/ Kontrolle|Ergebnisse
Row 2: ||Usual palliative care|
Row 3: Temel, J.S.|Fallzahl: N=77|Intervention(s)|QoL(tFAC-L)
Row 4: et al., 2010|||98,0/91,5/59/53,21/19
Row 5: |Setting: USA, single|Early palliative care,|
Row 6: [564],|center|monthly, with palliative|Gesamtmortalität
Row 7: ||care team|
Row

=== Intervention Extract 42 (Intervention) ===
cial support|
Row 44: |||
Row 45: ||3) symptom management|
Row 46: ||4) advanced care plan-|
Row 47: ||ning and unfinished busi-|
Row 48: ||ness|
Row 49: ||Kontrolle| Row 1: Studie|Studienpopulation|Intervention/ Kontrolle|Ergebnisse
Row 2: ||Usual palliative care|
Row 3: Temel, J.S.|Fallzahl: N=77|Intervention(s)|QoL(tFAC-L)
Row 4: et al., 2010|||98,0/91,5/59/53,21/19
Row 5: |Setting: USA, single|Early palliative care,|
Row 6: [564],|center|monthly, with palliative|Gesamtmortalität
Row 7: ||care team|
Row 8: |Patientencharakteris-||12,9/22,9 %
Row 9: |tika: 55% weiblich, Alter|routine oncology care|
Row

=== Intervention Extract 43 (Intervention) ===
ine oncology care|
Row 10: |||Biasrisiko:
Row 11: |im Mittel: 64 Jahre, 95%||
Row 12: ||Kontrolle|
Row 13: |kaukasisch||
Row 14: ||standard palliative care|
Row 15: |ECOG 0 41%||
Row 16: ||and routine oncology|
Row 17: |ECOG 1 47%|care|
Row 18: |Hirnmetastasen: 26%||
Row 19: Zimmer-|Fallzahl: N=461|Intervention(s)|Kein sign. Unterschied in
Row 20: mann, C. et|||der LQ
Row 21: |Setting: Canada, single|Early palliative care inter-|
Row 22: al., 2014|||
Row 23: |center, 16 medical on-|vention with pc physician|weitere Studien notwendig
Row 24: [609],|cologists, 24 clinics|and nurse|zur richtigen Patientenaus

=== Intervention Extract 44 (Intervention) ===
in
Row 20: mann, C. et|||der LQ
Row 21: |Setting: Canada, single|Early palliative care inter-|
Row 22: al., 2014|||
Row 23: |center, 16 medical on-|vention with pc physician|weitere Studien notwendig
Row 24: [609],|cologists, 24 clinics|and nurse|zur richtigen Patientenaus-
Row 25: |||wahl für die Intervention
Row 26: |Patientencharakteris-|once monthly, more often|
Row 27: |tika: 74% weiblich, Alter|necessary|Biasrisiko: keine komplette
Row 28: |im Mittel: 68 Jahre, 85%||Verblindung möglich, nur
Row 29: ||Content:|
Row 30: |kaukasisch||ein Zentrum
Row 31: ||Kontrolle|
Row 32: |||
Row 33: ||usual cancer

=== Intervention Extract 45 (Treatment) ===
n Respiratory Society
ean Society of Medical Oncology
kopischer Ultraschall
uordeoxyglukose-Positronenem
rtes exspiratorisches Volumen
last growth factor receptor
etastasen
tis-C-Virus
oxylin-Eosin-Färbung
ienprogramm Onkologie | Lungenk
ease-f
Epide
and T
ns
y
missio
karzino
free surviv
ermal Grow
Treatment o
onstomogra
om | Langve
val)
wth Factor Recep
of Cancer
aphie
ersion - 4.0 | April
ptor)
1.10 Abk
Abkür
zung
HER2
HIV
HLM
HPV
HR
HRQoL
IARC
IASLC
IC
ICD
ICD
IMRT
IO
IP
IPD
IQWiG
ITT
KHK
LD
LDCT
LDH
LK
LL
kürzun
r-
L
G
ngsverzeichnis
Erläuterung
Human Epidermal Growth Factor Rece
Human Immundefizie

=== Intervention Extract 46 (Treatment) ===
R
ORR
OS
kürzun
r-
C
G
ON
C
ngsverzeichnis
Erläuterung
Level of Evidence
Lokalrezidiv
Lung tumor screening and interventio
Multinational Association of Supportiv
melanoma inhibitory activity
Magnetresonanztomographie
nanoparticle albumin bound
National Comprehensive Cancer Netw
North Central Cancer Treatment Grou
Dutch-Belgian Randomized Lung Canc
Next generation sequencing
National Institute for Health and Care
National Institutes of Health
Negative Predictive Value
Non-Small-Cell Lung Cancer
Neuron-specific enolase
National Lung Screening Trial
neurotropher Tyrosinkinaserezeptor
Oligometastasierte Er

=== Intervention Extract 47 (Treatment) ===
er
nzgrad
ford 2009)
ford 2011)
ford 2011)
ford 2011)
ford 2011)
ford 2011)
© L
Methodik 29
Beschreibung
) Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
appraisal, or based on physiology, bench research or “first principles”
) Category - Does this intervention help? (Treatment Benefits): Systematic re-
view of randomized trials or n-of-1 trials
) Category - Does this intervention help? (Treatment Benefits): Randomized
trial or observational study with dramatic effect
) Category - Does this intervention help? (Treatment Benefits): Non-random-
ized controlled cohort/follow

=== Intervention Extract 48 (Treatment) ===
ion, Aetiology, Harm: Expert opinion without explicit critical
appraisal, or based on physiology, bench research or “first principles”
) Category - Does this intervention help? (Treatment Benefits): Systematic re-
view of randomized trials or n-of-1 trials
) Category - Does this intervention help? (Treatment Benefits): Randomized
trial or observational study with dramatic effect
) Category - Does this intervention help? (Treatment Benefits): Non-random-
ized controlled cohort/follow-up study (a systematic review is generally bet-
ter than an individual study)
) Category - Does this intervention help? (

=== Intervention Extract 49 (Treatment) ===
inciples”
) Category - Does this intervention help? (Treatment Benefits): Systematic re-
view of randomized trials or n-of-1 trials
) Category - Does this intervention help? (Treatment Benefits): Randomized
trial or observational study with dramatic effect
) Category - Does this intervention help? (Treatment Benefits): Non-random-
ized controlled cohort/follow-up study (a systematic review is generally bet-
ter than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Case-series,
case-control studies, or historically controlled studies (a systematic review is
generally

=== Intervention Extract 50 (Treatment) ===
Benefits): Randomized
trial or observational study with dramatic effect
) Category - Does this intervention help? (Treatment Benefits): Non-random-
ized controlled cohort/follow-up study (a systematic review is generally bet-
ter than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Case-series,
case-control studies, or historically controlled studies (a systematic review is
generally better than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Mechanism-
based reasoning
Hohe Qualität der Evidenz nach GRADE = Wir sind sehr sicher,

=== Intervention Extract 51 (Treatment) ===
review is generally bet-
ter than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Case-series,
case-control studies, or historically controlled studies (a systematic review is
generally better than an individual study)
) Category - Does this intervention help? (Treatment Benefits): Mechanism-
based reasoning
Hohe Qualität der Evidenz nach GRADE = Wir sind sehr sicher, dass der
wahre Effekt nahe bei dem Effektschätzer liegt.
Moderate Qualität nach GRADE = Wir haben mäßig viel Vertrauen in den Ef-
fektschätzer: Der wahre Effekt ist wahrscheinlich nahe bei dem Effekts

=== Intervention Extract 52 (Treatment) ===
sich durch Lokalthera-
pien, vorwiegend Bestrahlung oder Operation, behandeln lassen [1220], [1221],
[1222], [1223]. Ein derartiger Einsatz von ablativen Verfahren unter Fortführung der
bisherigen molekular-zielgerichteten Systemtherapie hat in mehreren retrospektiven
Studien zu einem Time-to-Next-Treatment Benefit (d.h. Hinauszögern des Systemthe-
rapiewechsels) von ca. 5-10 Monate im Median geführt und ist stets von einem Wech-
sel der Systemtherapie zu prüfen. Vorausssetzung für die Diagnose und Therapie ei-
ner Oligoprogression ist eine adäquate Bildgebung, idealerweise mit PET/CT und
Hirn-MRT.
Na

=== Intervention Extract 53 (Treatment) ===
apie nach Versagen von anderen Zweitge-
nerations-ALK-Inhibitoren erteilt wird. Real-world Daten aus dem Brigatinib Compas-
sionate-Use Program zeigen allerdings dass Brigatinib eine klinisch relevante Wirk-
samkeit bei vielen Patienten mit Lorlatinib-Versagen zeigt mit einer medianen Time-
to-Next-Treatment von 7.5 Monaten [1258]. Da Brigatinib auch besser verträglich als
die Chemotherapie, kann daher eine Therapieversuch mit Brigatinib nach Lorlatinib-
Versagen bei Fällen, die zuvor kein Brigatinib hatten, erwogen werden.
Ähnlich zu EGFR+ NSCLC kann auch bei ALK+ NSCLC zum Zeitpunkt des TKI-Versa-
ge

=== Intervention Extract 54 (Treatment) ===
en, erwogen werden.
Ähnlich zu EGFR+ NSCLC kann auch bei ALK+ NSCLC zum Zeitpunkt des TKI-Versa-
gens eine an 1-2 Orten beschränkte Oligoprogression in ca. 50% der Fälle auftreten.
Unter Anwendung von Lokaltherapien, vorwiegend Radiotherapie oder Chirurgie, be-
trägt der Benefit in der Time-to-Next-Treatment (d.h. das Hinauszögern des Sys-
temtherapiewechsels) im Median ca. 5-10 Monate [1221], [1259].
8.6 Stadi
EK
EK
Empfeh
B/0
Level of ium IV
hlungsg
f Eviden
V (ohne Indikation zur definitiven Lokaltherapie) 360
Therapie nach Versagen der zugelassenen ALK-Inhibitoren
Konsensbasierte Empfehlung geprüft

=== Intervention Extract 55 (Treatment) ===
m NSCLC war das ORR (primärer Endpunkt) 72% (95% CI, 54-75) in der
Erstlinie und 59% (95% CI, 80-136) nach Vorbehandlung mit Platin-basierter Chemo-
therapie. Das PFS betrug 13.0 und 16.5 Monate, die intrakranielle Ansprechrate 70%
bei Patienten mit messbaren ZNS-Metastasen. Die häufigsten Grad 3-4 treatment-rela-
ted adverse events (TRAEs) waren Neutropenie (18%), arterielle Hypertonie (10%), Se-
rum-CK Erhöhung (9%) und Lymphopenie (9%). Die Abbruchrate betrug 7%.
Systemtherapie bei Patienten mit MET Exon14 skipping Mu-
tation
Evidenzbasierte Empfehlung geprüft 2025
grad Patienten mit NSCLC Stadium I

=== Intervention Extract 56 (Treatment) ===
suchungen war eine cisplatinhaltige The-
rapie einer platinfreien Strategie überlegen Wolf et al. 1987 [1399], Havemann et al.
1987 [1368]. Eine Wirksamkeitsverstärkung durch Zugabe von Etoposid wurde auch
in einer Studie von Jackson et al 1984 [1400] gesehen. In der Studie der North Central
Cancer Treatment Group (NCCTG) [1401] führte die Addition von Etoposid zum ACO-
Schema bei LD-Patienten zur Verbesserung der Prognose. Dieses ACO-E-Schema
wurde in einer SWOG-Studie [1402] gegen das Alternieren von ACO und PE getestet,
wobei sich eine geringe Verlängerung der medianen Überlebenszeit (16.5 vs 15.1
M

=== Intervention Extract 57 (Treatment) ===
9;354:1837-1838. URL:
492. North American Symptomatic Carotid Endarterectomy Trial C. Beneficial effect of carotid
endarterectomy in symptomatic patients with high-grade carotid stenosis. N.Engl.J.Med.
506. Elkin EB, Kim SH, Casper ES, Kissane DW, Schrag D. Desire for information and involvement in
treatment decisions: elderly cancer patients' preferences and their physicians' perceptions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
520. Zachariae R, Pedersen CG, Jensen AB, Ehrnrooth E, Rossen PB, von der Maase H. Association
of perceived physician comm

=== Intervention Extract 58 (Treatment) ===
Turkiewicz KL, Allen M. An evidence base for patient-centered can-
cer care: a meta-analysis of studies of observed communication between cancer specialists
and their patients. Patient Educ Couns. 2009;77:379-83. URL:
567. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a
meta-analysis. Med Care. 2009;47:826-34. URL:
cles/PMC2728700/
579. Arnold EM, Artin KA, Person JL, Griffith DL. Consideration of hastening death among hospice
patients and their families. J Pain Symptom Manage. 2004;27:523-32. URL:
580. Kohlwes RJ, Koepsell TD, Rhodes LA, Pearlman RA. Physician

=== Intervention Extract 59 (Treatment) ===
ir families. J Pain Symptom Manage. 2004;27:523-32. URL:
580. Kohlwes RJ, Koepsell TD, Rhodes LA, Pearlman RA. Physicians' responses to patients' requests
for physician-assisted suicide. Arch Intern Med. 2001;161:657-63. URL:
593. Nagasaki F, Flehinger BJ, Martini N. Complications of surgery in the treatment of carcinoma of
the lung. Chest. 1982;82:25-29. URL:
622. Okada M, Yoshikawa K, Hatta T, Tsubota N. Is segmentectomy with lymph node assessment
an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller?.
Ann.Thorac.Surg. 2001;71:956-960. URL:
623. Date H, Andou A, Shimizu N. The

=== Intervention Extract 60 (Treatment) ===
cancer. Lung Cancer. 2002;36:1-6. URL:
687. Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang-Peng J. A phase I feasibility and pharmaco-
kinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anticancer
Drugs. 1997;8:565-573. URL:
688. Scott WJ, Howington J, Movsas B. Treatment of stage II non-small cell lung cancer. Chest.
Clin Oncol Vol 20, 2603-4 and 2604-5). J Clin Oncol. 2002;20:247-253. URL:
(Comment to Marino, P, Cancer, Vol 76, p 593 - 601). Cancer. 1996;77:2413-2414. URL:
Cancer Institute of Canada and intergroup trial JBR10 and a review of the literature. Lung
C

=== Intervention Extract 61 (Treatment) ===
y 9730). J Clin Oncol. 2005;23:190-6. URL:
med/15625373
lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31:3004-11. URL:
med.ncbi.nlm.nih.gov/23835708/
Osterlind, K, Lung Cancer Vol 19, p 99-100). Lung Cancer. 1998;19:141-151. URL:
1387. Osterlind K, Hansen M, Hansen HH, Dombernowsky P, Rorth M. Treatment policy of surgery
in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive pa-
tients. Thorax. 1985;40:272-277. URL:
1388. Waddell TK, Shepherd FA. Should aggressive surgery ever be part of the management of
small cell lung cancer?. Thorac.Surg.Clin. 2004;14:271-28

=== Intervention Extract 62 (Treatment) ===
of Programmed Cell Death
Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis. Front Oncol.
doxorubicin, and etoposide: a non-cross-resistant schedule. J.Clin.Oncol. 1999;17:927-932.
URL:
brain radiotherapy--a phase III study of the European Organization for the Research and
Treatment of Cancer Lung Cancer Cooperative Group. J.Clin.Oncol. 2000;18:3400-3408. URL:
1506. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusion. Cochrane-database-of-system-
atic-reviews. 2004;(1): URL:
1507. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusion. Cochrane-database-of-sys

=== Intervention Extract 63 (Treatment) ===
ll-bore, tunneled pleural catheters. Respiration. 2004;71:559-566. URL:
1537. Varricchio C. Clinical management of superior vena cava syndrome. Heart Lung.
1553. George PJ, Clarke G, Tolfree S, Garrett CP, Hetzel MR. Changes in regional ventilation and per-
fusion of the lung after endoscopic laser treatment. Thorax. 1990;45:248-253. URL:
1554. Casey KR, Fairfax WR, Smith SJ, Dixon JA. Intratracheal fire ignited by the Nd-YAG laser during
treatment of tracheal stenosis. Chest. 1983;84:295-296. URL:
1555. Vanderschueren RG, Westermann CJ. Complications of endobronchial neodymium-Yag
(Nd:Yag) laser appli

=== Intervention Extract 64 (Treatment) ===
Heart Lung.
1553. George PJ, Clarke G, Tolfree S, Garrett CP, Hetzel MR. Changes in regional ventilation and per-
fusion of the lung after endoscopic laser treatment. Thorax. 1990;45:248-253. URL:
1554. Casey KR, Fairfax WR, Smith SJ, Dixon JA. Intratracheal fire ignited by the Nd-YAG laser during
treatment of tracheal stenosis. Chest. 1983;84:295-296. URL:
1555. Vanderschueren RG, Westermann CJ. Complications of endobronchial neodymium-Yag
(Nd:Yag) laser application. Lung. 1990;168 Suppl:1089-1094. URL:
1556. Freitag L, Chapman GA, Sielczak M, Ahmed A, Russin D. Laser smoke effect on the bronchial
sy

=== Intervention Extract 65 (Treatment) ===
icone prostheses. Ann.Otol.Rhi-
nol.Laryngol. 1998;107:149-154. URL:
1616. Wilhelm K, Schild H, Duber C, Mitze M, Schlegel J, Lorenz J. [Stent implantation as a palliative
therapeutic measure in stenosing tumors of central airways]. Rofo. 1996;164:496-501. URL:
1617. Wilson GE, Walshaw MJ, Hind CR. Treatment of large airway obstruction in lung cancer using
expandable metal stents inserted under direct vision via the fibreoptic bronchoscope. Tho-
rax. 1996;51:248-252. URL:
1618. Witt C, Dinges S, Schmidt B, Ewert R, Budach V, Baumann G. Temporary tracheobronchial
stenting in malignant stenoses. Eur.J.Ca

=== Intervention Extract 66 (Treatment) ===
J
Palliat Care. 2011;27:28-36. URL:
1697. King SJ, Reid C, Forbes K, Hanks G. A systematic review of oxycodone in the management of
cancer pain. Palliative Medicine. 2011;25:454-470. URL:
med.ncbi.nlm.nih.gov/21708852/
1698. Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a sys-
tematic review. Palliat Med. 2011;25:471-7. URL:
med/21708853
review of practices and effects. Annals of Oncology. 2011;22:1478-86. URL:
1727. Lübbe A. S. KV. Konzepte onkologischer Rehabilitation. Therapiekonzepte Onkologie. 2003
1728. Fialka-Moser V, Crevenna R, Korpan M, Quittan M. Cance

=== Intervention Extract 67 (Treatment) ===
KV. Konzepte onkologischer Rehabilitation. Therapiekonzepte Onkologie. 2003
1728. Fialka-Moser V, Crevenna R, Korpan M, Quittan M. Cancer rehabilitation: particularly with as-
pects on physical impairments. J.Rehabil.Med. 2003;35:153-162. URL:
1729. Nazarian J. Cardiopulmonary rehabilitation after treatment for lung cancer. Curr.Treat Op-
tions.Oncol. 2004;5:75-82. URL:
1730. Spruit MA, Janssen PP, Willemsen SC, Hochstenbag MM, Wouters EF. Exercise capacity before
and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients:
a pilot study. Lung Cancer. 2006;52:257-260

=== Intervention Extract 68 (Treatment) ===
ECOG|Eastern Cooperative Oncology Group
Row 11: ED|Extensive disease
Row 12: EGFR|Epidermaler Wachstumsfaktor (engl. Epidermal Growth Factor Receptor)
Row 13: EK|Expertenkonsens
Row 14: EKG|Elektrokardiogramm
Row 15: EMA|European Medicines Agency
Row 16: EORTC|European Organisation for Research and Treatment of Cancer
Row 17: EQ-5D|European Quality of Life 5 Dimensions
Row 18: ERS|European Respiratory Society
Row 19: ESMO|European Society of Medical Oncology
Row 20: EUS|Endoskopischer Ultraschall
Row 21: FDG-PET|18F-Fluordeoxyglukose-Positronenemissionstomographie
Row 22: FEV|Forciertes exspiratorische

=== Intervention Extract 69 (Treatment) ===
Row 11: Epide
Row 12: 
Row 13: 
Row 14: 
Row 15: and T
Row 16: ns
Row 17: 
Row 18: y
Row 19: 
Row 20: missio
Row 21: 
Row 22: 
Row 23: 
Row 24: 
Row 25:  Row 1: 
Row 2: 
Row 3: free surviv
Row 4: 
Row 5: 
Row 6: 
Row 7: 
Row 8: 
Row 9: 
Row 10: 
Row 11: ermal Grow
Row 12: 
Row 13: 
Row 14: 
Row 15: Treatment o
Row 16: 
Row 17: 
Row 18: 
Row 19: 
Row 20: onstomogra
Row 21: 
Row 22: 
Row 23: 
Row 24: 
Row 25:  Row 1: 
Row 2: 
Row 3: val)
Row 4: 
Row 5: 
Row 6: 
Row 7: 
Row 8: 
Row 9: 
Row 10: 
Row 11: wth Factor Recep
Row 12: 
Row 13: 
Row 14: 
Row 15: of Cancer
Row 16: 
Row 17: 
Row 18: 
Row 19: 
Row 20

=== Intervention Extract 70 (Treatment) ===
eening and intervention trial
Row 7: MASCC|Multinational Association of Supportive Care in Cancer
Row 8: MIA|melanoma inhibitory activity
Row 9: MRT|Magnetresonanztomographie
Row 10: Nab|nanoparticle albumin bound
Row 11: NCCN|National Comprehensive Cancer Network
Row 12: NCCTG|North Central Cancer Treatment Group
Row 13: NELSON|Dutch-Belgian Randomized Lung Cancer Screening Trial
Row 14: NGS|Next generation sequencing
Row 15: NICE|National Institute for Health and Care Excellence
Row 16: NIH|National Institutes of Health
Row 17: NPV|Negative Predictive Value
Row 18: NSCLC|Non-Small-Cell Lung Cancer
Ro

=== Intervention Extract 71 (Treatment) ===
dence
Row 5: |Lokalrezidiv
Row 6: |Lung tumor screening and interventio
Row 7: |Multinational Association of Supportiv
Row 8: |melanoma inhibitory activity
Row 9: |Magnetresonanztomographie
Row 10: |nanoparticle albumin bound
Row 11: |National Comprehensive Cancer Netw
Row 12: |North Central Cancer Treatment Grou
Row 13: |Dutch-Belgian Randomized Lung Canc
Row 14: |Next generation sequencing
Row 15: |National Institute for Health and Care
Row 16: |National Institutes of Health
Row 17: |Negative Predictive Value
Row 18: |Non-Small-Cell Lung Cancer
Row 19: |Neuron-specific enolase
Row 20: |National Lung

=== Intervention Extract 72 (Treatment) ===
es)
Row 20: | Row 1: Evidenzgrad|Beschreibung
Row 2: 5 (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: 1 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: 2 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: 3 (Oxford 2011)|Category - Does this inte

=== Intervention Extract 73 (Treatment) ===
isal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: 1 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: 2 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: 3 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter t

=== Intervention Extract 74 (Treatment) ===
ematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: 2 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: 3 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individual study)
Row 15: 4 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or histori

=== Intervention Extract 75 (Treatment) ===
Row 11: 3 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individual study)
Row 15: 4 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controlled studies (a systematic review is
Row 17: |
Row 18: |generally better than an individual study)
Row 19: 5 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Mechanism-
Row 20: |based reasoning
R

=== Intervention Extract 76 (Treatment) ===
d 2011)|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controlled studies (a systematic review is
Row 17: |
Row 18: |generally better than an individual study)
Row 19: 5 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Mechanism-
Row 20: |based reasoning
Row 21: |
Row 22: ⊕⊕⊕⊕|Hohe Qualität der Evidenz nach GRADE = Wir sind sehr sicher, dass der
Row 23: |wahre Effekt nahe bei dem Effektschätzer liegt.
Row 24: |
Row 25: ⊕⊕⊕⊝|Moderate Qualität nach GRADE = Wir haben mäßig viel Vertrauen in den Ef-
Row 26

=== Intervention Extract 77 (Treatment) ===
⊕⊝
Row 17: 
Row 18: ⊝⊝
Row 19: 
Row 20: ⊝⊝
Row 21:  Row 1: |Beschreibung
Row 2: )|Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: )|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: )|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: )|Category - Does this intervention help? (Treatment Be

=== Intervention Extract 78 (Treatment) ===
licit critical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: )|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: )|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: )|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individ

=== Intervention Extract 79 (Treatment) ===
? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row 7: |
Row 8: )|Category - Does this intervention help? (Treatment Benefits): Randomized
Row 9: |trial or observational study with dramatic effect
Row 10: |
Row 11: )|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individual study)
Row 15: )|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controll

=== Intervention Extract 80 (Treatment) ===
th dramatic effect
Row 10: |
Row 11: )|Category - Does this intervention help? (Treatment Benefits): Non-random-
Row 12: |ized controlled cohort/follow-up study (a systematic review is generally bet-
Row 13: |
Row 14: |ter than an individual study)
Row 15: )|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controlled studies (a systematic review is
Row 17: |
Row 18: |generally better than an individual study)
Row 19: )|Category - Does this intervention help? (Treatment Benefits): Mechanism-
Row 20: |based reasoning
Row 21: |
Row 2

=== Intervention Extract 81 (Treatment) ===
dual study)
Row 15: )|Category - Does this intervention help? (Treatment Benefits): Case-series,
Row 16: |case-control studies, or historically controlled studies (a systematic review is
Row 17: |
Row 18: |generally better than an individual study)
Row 19: )|Category - Does this intervention help? (Treatment Benefits): Mechanism-
Row 20: |based reasoning
Row 21: |
Row 22: |Hohe Qualität der Evidenz nach GRADE = Wir sind sehr sicher, dass der
Row 23: |wahre Effekt nahe bei dem Effektschätzer liegt.
Row 24: |
Row 25: |Moderate Qualität nach GRADE = Wir haben mäßig viel Vertrauen in den Ef-
Row 26: |fekts

=== Intervention Extract 82 (Drug) ===
V (ohne Indikation zur definitiven Lokaltherapie) 375
Systemtherapie bei Patienten mit HER2-Mutation
Evidenzbasierte Empfehlung neu 2025
grad Patienten mit NSCLC Stadium IV mit einer HER2 Mutation sollte nach Versagen
mindestens einer Systemtherapie eine zielgerichtete Therapie mit dem Antikör-
per-Drug Konjugat Trastuzumab deruxtecan angeboten werden. Starker Konsens 6.4 mg/kg Trastuzumab deruxtecan (T-DXd) alle 3 Wochen eine Ansprechrate von
55%, eine mediane Ansprechdauer von 9,3 Monaten, ein medianes progressionsfreie Zulassungsstudie zu T-DXd für vorbehaldente Patienten (DESTINY-Lung02) i.v.

=== Intervention Extract 83 (Drug) ===
pie CHECKMATE 331 [1487] wurden insgesamt 569
Patienten eingeschlossen und auf einen Therapiearm mit Nivolumab oder Topotecan
bzw Amrubicin randomisiert. Der Unterschied im medianen Gesamtüberleben war
nicht statistisch signifikant.
Neue Therapieansätze - Bispezifische Antikörper und ADCs (antibody-drug-conju-
gate)
Auf dem ESMO 2023 wurden Daten zu Tarlatamab, einem bispezifischen T-cell enga-
ger mit Bindung sowohl an DLL3 als auch an CD3 auf den T-Zellen, vorgestellt. Im
Rahmen der Phase II DeLLphi-301-Studie wurden jeweils 88 Patienten, die zuvor min-
destens 2 Therapielinien erhalten hatten,

=== Intervention Extract 84 (Drug) ===
Immuncheck-
point-Inhibitor Therapie eine zielge-
richtete Therapie mit einem KRAS In-
hibitor (Adagrasib oder Sotorasib)
angeboten werden.
Patienten mit NSCLC Stadium IV mit
einer HER2 Mutation sollte nach Ver-
sagen mindestens einer Systemthe-
rapie eine zielgerichtete Therapie
mit dem Antikörper-Drug Konjugat
Trastuzumab deruxtecan angeboten
werden.
In Anbetracht der Dynamik der Ent-
wicklung neuer personalisierter The-
rapieansätze sollte angestrebt wer-
den dass jeder Patient mit NSCLC
Stadium IV vor der Erstlinientherapie-
entscheidung eine umfassende NGS-
basierte Molekulardiagnostik erhält

=== Intervention Extract 85 (Drug) ===
erfügbar in DE|
Row 8: |Starker Konsens|
Row 9: || Row 1: 8.153|Evidenzbasierte Empfehlung|neu 2025
Row 2: Empfehlungsgrad|Patienten mit NSCLC Stadium IV mit einer HER2 Mutation sollte nach Versagen|
Row 3: A|mindestens einer Systemtherapie eine zielgerichtete Therapie mit dem Antikör-|
Row 4: |per-Drug Konjugat Trastuzumab deruxtecan angeboten werden.|
Row 5: Level of Evidence|[1303], [1304], [1305]|
Row 6: 1||
Row 7: ||
Row 8: |Starker Konsens|
Row 9: || Row 1: 8.153
Row 2: Empfeh
Row 3: A
Row 4: Level of
Row 5: 1
Row 6: 
Row 7:  Row 1: 3
Row 2: hlungsg
Row 3: 
Row 4: f Eviden
Row 5: 
Row 6: 
Ro

=== Intervention Extract 86 (Drug) ===
1: 3
Row 2: hlungsg
Row 3: 
Row 4: f Eviden
Row 5: 
Row 6: 
Row 7:  Row 1: |Evidenzbasierte Empfehlung|neu 2025
Row 2: grad|Patienten mit NSCLC Stadium IV mit einer HER2 Mutation sollte nach Versagen|
Row 3: |mindestens einer Systemtherapie eine zielgerichtete Therapie mit dem Antikör-|
Row 4: |per-Drug Konjugat Trastuzumab deruxtecan angeboten werden.|
Row 5: nce|[1303], [1304], [1305]|
Row 6: ||
Row 7: ||
Row 8: |Starker Konsens|
Row 9: || Row 1: 8.154|Konsensbasierte Empfehlung|modifiziert 2025
Row 2: EK|In Anbetracht der Dynamik der Entwicklung neuer personalisierter Therapiean-|
Row 3: |sätze

=== Intervention Extract 87 (Drug) ===
oder Sotorasib)|
Row 27: ||
Row 28: |angeboten werden.|
Row 29: |8.152|neu 2024
Row 30: |Patienten mit NSCLC Stadium IV mit|
Row 31: |einer HER2 Mutation sollte nach Ver-|
Row 32: ||
Row 33: |sagen mindestens einer Systemthe-|
Row 34: |rapie eine zielgerichtete Therapie|
Row 35: |mit dem Antikörper-Drug Konjugat|
Row 36: |Trastuzumab deruxtecan angeboten|
Row 37: |werden.|
Row 38: 8.146|8.153|modifiziert
Row 39: ||2024
Row 40: In Anbetracht der Dynamik der Entwick-|In Anbetracht der Dynamik der Ent-|
Row 41: ||
Row 42: lung neuer personalisierter Therapiean-|wicklung neuer personalisierter The-|
R

=== Intervention Extract 88 (Drug) ===
bitor (Adagrasib oder Sotorasib)
Row 23: |
Row 24: |angeboten werden.
Row 25: |8.152
Row 26: |Patienten mit NSCLC Stadium IV mit
Row 27: |einer HER2 Mutation sollte nach Ver-
Row 28: |
Row 29: |sagen mindestens einer Systemthe-
Row 30: |rapie eine zielgerichtete Therapie
Row 31: |mit dem Antikörper-Drug Konjugat
Row 32: |Trastuzumab deruxtecan angeboten
Row 33: |werden.
Row 34: |8.153
Row 35: |In Anbetracht der Dynamik der Ent-
Row 36: |wicklung neuer personalisierter The-
Row 37: |rapieansätze sollte angestrebt wer-
Row 38: |den dass jeder Patient mit NSCLC
Row 39: |Stadium IV vor der Erstlinient

=== Intervention Extract 89 (Therapy) ===
lisierungen wurde das System des Oxford Centre for Evidence-based
Medicine in der Version von 2011 sowie zu einzelnen Fragen das GRADE-Systems
(Grading of Recommendations Assessment, Development and Evaluation)
e 4: Übersicht der verwendeten Evidenzgraduierungsysteme
nzgrad Beschreibung
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of RCTs
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
dence Interval)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of cohort studies
xford 2009) Therapy/P

=== Intervention Extract 90 (Therapy) ===
2011 sowie zu einzelnen Fragen das GRADE-Systems
(Grading of Recommendations Assessment, Development and Evaluation)
e 4: Übersicht der verwendeten Evidenzgraduierungsysteme
nzgrad Beschreibung
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of RCTs
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
dence Interval)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of cohort studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
quality RCT; e.g., <80 % fo

=== Intervention Extract 91 (Therapy) ===
and Evaluation)
e 4: Übersicht der verwendeten Evidenzgraduierungsysteme
nzgrad Beschreibung
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of RCTs
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
dence Interval)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of cohort studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
quality RCT; e.g., <80 % follow-up)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of ca

=== Intervention Extract 92 (Therapy) ===
) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of RCTs
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
dence Interval)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of cohort studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
quality RCT; e.g., <80 % follow-up)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of case-control studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
ford 2

=== Intervention Extract 93 (Therapy) ===
y, Harm: Individual RCT (with narrow Confi-
dence Interval)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of cohort studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
quality RCT; e.g., <80 % follow-up)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of case-control studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
ford 2009) Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
and case-control studies)
2.2 Grun
Eviden
5 (

=== Intervention Extract 94 (Therapy) ===
ystematic Review (with homogeneity)
of cohort studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
quality RCT; e.g., <80 % follow-up)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of case-control studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
ford 2009) Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
and case-control studies)
2.2 Grun
Eviden
5 (Oxf
1 (Oxf
2 (Oxf
3 (Oxf
4 (Oxf
5 (Oxf
ndlagen der
nzgrad
ford 2009)
ford 2011)
ford 2011)
ford 2011)
ford 201

=== Intervention Extract 95 (Therapy) ===
ention, Aetiology, Harm: Individual cohort study (including low
quality RCT; e.g., <80 % follow-up)
xford 2009) Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
of case-control studies
xford 2009) Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
ford 2009) Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
and case-control studies)
2.2 Grun
Eviden
5 (Oxf
1 (Oxf
2 (Oxf
3 (Oxf
4 (Oxf
5 (Oxf
ndlagen der
nzgrad
ford 2009)
ford 2011)
ford 2011)
ford 2011)
ford 2011)
ford 2011)
© L
Methodik 29
Beschreibung
) Therapy/Prevention, Aetiology, Ha

=== Intervention Extract 96 (Therapy) ===
-Control Study
ford 2009) Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
and case-control studies)
2.2 Grun
Eviden
5 (Oxf
1 (Oxf
2 (Oxf
3 (Oxf
4 (Oxf
5 (Oxf
ndlagen der
nzgrad
ford 2009)
ford 2011)
ford 2011)
ford 2011)
ford 2011)
ford 2011)
© L
Methodik 29
Beschreibung
) Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
appraisal, or based on physiology, bench research or “first principles”
) Category - Does this intervention help? (Treatment Benefits): Systematic re-
view of randomized trials or n-of-1 trials
) Category - Does this intervention

=== Intervention Extract 97 (Therapy) ===
i B, Decook C, Haura E, Chellappan S. Nicotine inhibits apoptosis
induced by chemotherapeutic drugs by up-regulating XIAP and survivin.
Proc.Natl.Acad.Sci.U.S.A. 2006;103:6332-6337. URL:
med/16601104
79. Fox JL, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation
therapy for non-small cell lung cancer. Lung Cancer. 2004;44:287-293. URL:
120. Korte JE, Brennan P, Henley SJ, Boffetta P. Dose-specific meta-analysis and sensitivity analysis
of the relation between alcohol consumption and lung cancer risk. Am.J.Epidemiol.
134. Hong WK, Benner SE, Lippman SM. Evolution o

=== Intervention Extract 98 (Therapy) ===
hebungsbögen, Kennzahlen und Checklisten im Überblick.
2021; URL:
Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell
Lung Cancer. J Clin Oncol. 2016;34(9):953-62. URL:
med.ncbi.nlm.nih.gov/26811519/
951. Ilonen I, Jones D. Initial extended resection or neoadjuvant therapy for T4 non-small cell lung
cancer-What is the evidence?. Shanghai Chest. 2018;2: URL:
med.ncbi.nlm.nih.gov/30498811/
outcome. Ann Thorac Surg. 2012;94(6):1815-22. URL:
med.ncbi.nlm.nih.gov/23103000/
1000. Huber R, Reck M, Thomas M. Current status of and future strategies for multimodality treat-
me

=== Intervention Extract 99 (Therapy) ===
stage III nonsmall cell lung cancer. Eur Respir J. 2013;42(4):1119-33.
URL:
lung cancer: exploratory subgroup analyses of the NVALT-11/DLCRG-02 phase-III study. Acta
Oncol. 2019;58(10):1528-1531. URL:
1013. Baker S, Dahele M, Lagerwaard F, Senan S. A critical review of recent developments in radio-
therapy for non-small cell lung cancer. Radiat Oncol. 2016;11(1):115. URL:
med.ncbi.nlm.nih.gov/27600665/
1014. Jumeau R, Vilotte F, Durham A, Ozsahin E. Current landscape of palliative radiotherapy for
non-small-cell lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 2):S192-S201. URL:
1015. Stevens R, Mac

=== Intervention Extract 100 (Therapy) ===
ddition to supportive care improves survival in advanced non-
small-cell lung cancer: a systematic review and meta-analysis of individual patient data from
16 randomized controlled trials. J Clin Oncol. 2008;26:4617-25. URL:
1061. Kong FM, Ten HR, Eisbruch A, Lawrence TS. Non-small cell lung cancer therapy-related pulmo-
nary toxicity: an update on radiation pneumonitis and fibrosis. Semin.Oncol. 2005;32:S42-
S54. URL:
1073. Chang DT, Zlotecki RA, Olivier KR. Re-examining the role of elective nodal irradiation: finding
ways to maximize the therapeutic ratio. Am.J Clin Oncol. 2005;28:597-602. URL:
107

=== Intervention Extract 101 (Therapy) ===
er?. Thorac.Surg.Clin. 2004;14:271-281. URL:
1389. Wakeam E, Giuliani M, Leighl N, Finlayson S, Varghese T, Darling G. Indications for Adjuvant
Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer. Ann Thorac Surg.
1410. Perry MC, Herndon JE, Eaton WL, Green MR. Thoracic radiation therapy added to chemother-
apy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.
J.Clin.Oncol. 1998;16:2466-2467. URL:
chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol. 1984;2:1200-
cancer (CONVERT): an open-label, phase 3, randomised, superior

=== Intervention Extract 102 (Therapy) ===
Golish JA, Ahmad M. Survival experience following
Nd:YAG laser photoresection for primary bronchogenic carcinoma. Chest. 1988;94:939-944.
URL:
1559. Hetzel MR, Smith SG. Endoscopic palliation of tracheobronchial malignancies. Thorax.
1583. 10 cm in diameter after complete remission by photodynamic therapy. Chest.
1612. Vonk-Noordegraaf A, Postmus PE, Sutedja TG. Tracheobronchial stenting in the terminal care
of cancer patients with central airways obstruction. Chest. 2001;120:1811-1814. URL:
1613. Wassermann K, Eckel HE, Michel O, Muller RP. Emergency stenting of malignant obstruction
of the upper a

=== Intervention Extract 103 (Therapy) ===
bstructive pulmonary disease A systematic review. Ann Am Thorac
Soc. 2015;12(7):1079-92. URL:
1669. Clemens KE, Klaschik E. Effect of hydromorphone on ventilation in palliative care patients
with dyspnea. Support Care Cancer. 2008;16:93-9. URL:
med/17929063
1670. Clemens KE, Klaschik E. Symptomatic therapy of dyspnea with strong opioids and its effect
on ventilation in palliative care patients. J Pain Symptom Manage. 2007;33:473-81. URL:
1682. Booth S, Moffat C, Farquhar M, Higginson IJ, Burkin J. Developing a breathlessness interven-
tion service for patients with palliative and supportive care need

=== Intervention Extract 104 (Therapy) ===
Row 9:  Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6: 
Row 7: eitsorganis
Row 8: 
Row 9:  Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6: 
Row 7: sation)
Row 8: 
Row 9:  Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6: 
Row 7: 
Row 8: 
Row 9:  Row 1: Evidenzgrad|Beschreibung
Row 2: 1a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 3: |of RCTs
Row 4: |
Row 5: 1b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
Row 6: |dence Interval)
Row 7: |
Row 8: 2a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review

=== Intervention Extract 105 (Therapy) ===
Row 5: 
Row 6: 
Row 7: sation)
Row 8: 
Row 9:  Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6: 
Row 7: 
Row 8: 
Row 9:  Row 1: Evidenzgrad|Beschreibung
Row 2: 1a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 3: |of RCTs
Row 4: |
Row 5: 1b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
Row 6: |dence Interval)
Row 7: |
Row 8: 2a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 9: |of cohort studies
Row 10: |
Row 11: 2b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Indivi

=== Intervention Extract 106 (Therapy) ===
videnzgrad|Beschreibung
Row 2: 1a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 3: |of RCTs
Row 4: |
Row 5: 1b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
Row 6: |dence Interval)
Row 7: |
Row 8: 2a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 9: |of cohort studies
Row 10: |
Row 11: 2b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: 3a (Oxford 2009)|Therapy/Preventi

=== Intervention Extract 107 (Therapy) ===
Ts
Row 4: |
Row 5: 1b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
Row 6: |dence Interval)
Row 7: |
Row 8: 2a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 9: |of cohort studies
Row 10: |
Row 11: 2b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: 3a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 15: |of case-control studies
Row 16: |
Row 17: 3b (Oxford 2009)|Therapy/P

=== Intervention Extract 108 (Therapy) ===
rd 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 9: |of cohort studies
Row 10: |
Row 11: 2b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: 3a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 15: |of case-control studies
Row 16: |
Row 17: 3b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
Row 18: 4 (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort

=== Intervention Extract 109 (Therapy) ===
)|Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: 3a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 15: |of case-control studies
Row 16: |
Row 17: 3b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
Row 18: 4 (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
Row 19: |and case-control studies)
Row 20: | Row 1: Eviden
Row 2: 1a (Ox
Row 3: 
Row 4: 1b (Ox
Row 5: 
Row 6: 2a (Ox
Row 7: 
Row 8: 2b (Ox
Row

=== Intervention Extract 110 (Therapy) ===
ity RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: 3a (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 15: |of case-control studies
Row 16: |
Row 17: 3b (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
Row 18: 4 (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
Row 19: |and case-control studies)
Row 20: | Row 1: Eviden
Row 2: 1a (Ox
Row 3: 
Row 4: 1b (Ox
Row 5: 
Row 6: 2a (Ox
Row 7: 
Row 8: 2b (Ox
Row 9: 
Row 10: 3a (Ox
Row 11: 
Row 12: 3b (Ox
Row 13: 4 (Oxf
Row 14:  Row 1: nzgrad|Beschreib

=== Intervention Extract 111 (Therapy) ===
Harm: Case-series (and poor quality cohort
Row 19: |and case-control studies)
Row 20: | Row 1: Eviden
Row 2: 1a (Ox
Row 3: 
Row 4: 1b (Ox
Row 5: 
Row 6: 2a (Ox
Row 7: 
Row 8: 2b (Ox
Row 9: 
Row 10: 3a (Ox
Row 11: 
Row 12: 3b (Ox
Row 13: 4 (Oxf
Row 14:  Row 1: nzgrad|Beschreibung
Row 2: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 3: |of RCTs
Row 4: |
Row 5: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
Row 6: |dence Interval)
Row 7: |
Row 8: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homo

=== Intervention Extract 112 (Therapy) ===
ow 3: 
Row 4: 1b (Ox
Row 5: 
Row 6: 2a (Ox
Row 7: 
Row 8: 2b (Ox
Row 9: 
Row 10: 3a (Ox
Row 11: 
Row 12: 3b (Ox
Row 13: 4 (Oxf
Row 14:  Row 1: nzgrad|Beschreibung
Row 2: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 3: |of RCTs
Row 4: |
Row 5: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
Row 6: |dence Interval)
Row 7: |
Row 8: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 9: |of cohort studies
Row 10: |
Row 11: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual cohor

=== Intervention Extract 113 (Therapy) ===
xf
Row 14:  Row 1: nzgrad|Beschreibung
Row 2: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 3: |of RCTs
Row 4: |
Row 5: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
Row 6: |dence Interval)
Row 7: |
Row 8: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 9: |of cohort studies
Row 10: |
Row 11: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: xford 2009)|Therapy/Prevention, Aetiol

=== Intervention Extract 114 (Therapy) ===
)
Row 3: |of RCTs
Row 4: |
Row 5: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual RCT (with narrow Confi-
Row 6: |dence Interval)
Row 7: |
Row 8: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 9: |of cohort studies
Row 10: |
Row 11: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 15: |of case-control studies
Row 16: |
Row 17: xford 2009)|Therapy/Prevention,

=== Intervention Extract 115 (Therapy) ===
Row 8: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 9: |of cohort studies
Row 10: |
Row 11: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 15: |of case-control studies
Row 16: |
Row 17: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
Row 18: ford 2009)|Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
Row 19: |a

=== Intervention Extract 116 (Therapy) ===
xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 15: |of case-control studies
Row 16: |
Row 17: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
Row 18: ford 2009)|Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
Row 19: |and case-control studies)
Row 20: | Row 1: Evidenzgrad|Beschreibung
Row 2: 5 (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Expert opi

=== Intervention Extract 117 (Therapy) ===
w
Row 12: |quality RCT; e.g., <80 % follow-up)
Row 13: |
Row 14: xford 2009)|Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogeneity)
Row 15: |of case-control studies
Row 16: |
Row 17: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
Row 18: ford 2009)|Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
Row 19: |and case-control studies)
Row 20: | Row 1: Evidenzgrad|Beschreibung
Row 2: 5 (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
Row 3: |appraisal, or based on physiology, bench resear

=== Intervention Extract 118 (Therapy) ===
l studies
Row 16: |
Row 17: xford 2009)|Therapy/Prevention, Aetiology, Harm: Individual Case-Control Study
Row 18: ford 2009)|Therapy/Prevention, Aetiology, Harm: Case-series (and poor quality cohort
Row 19: |and case-control studies)
Row 20: | Row 1: Evidenzgrad|Beschreibung
Row 2: 5 (Oxford 2009)|Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: 1 (Oxford 2011)|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-o

=== Intervention Extract 119 (Therapy) ===
0: ⊕⊝⊝
Row 21:  Row 1: nzgrad
Row 2: ford 2009)
Row 3: 
Row 4: ford 2011)
Row 5: 
Row 6: ford 2011)
Row 7: 
Row 8: ford 2011)
Row 9: 
Row 10: ford 2011)
Row 11: 
Row 12: ford 2011)
Row 13: 
Row 14: ⊕⊕
Row 15: 
Row 16: ⊕⊝
Row 17: 
Row 18: ⊝⊝
Row 19: 
Row 20: ⊝⊝
Row 21:  Row 1: |Beschreibung
Row 2: )|Therapy/Prevention, Aetiology, Harm: Expert opinion without explicit critical
Row 3: |appraisal, or based on physiology, bench research or “first principles”
Row 4: |
Row 5: )|Category - Does this intervention help? (Treatment Benefits): Systematic re-
Row 6: |view of randomized trials or n-of-1 trials
Row

=== Intervention Extract 120 (Dose) ===
Autoren dieses Unterkapitels Struktur, Textpassagen und Tabellen ihres eige-
nen, durch mehrere Fachgesellschaften in 2023 konsentierten Positionspapiers zur
Implementierung eines nationalen organisierten Programms in Deutschland zur Früh-
erkennung von Lungenkrebs in Risikopopulationen mittels Low-dose-CT-Screening
inklusive Management von abklärungsbedürftigen Screeningbefunden eingearbeitet,
nachdem sie diese unter Einbeziehung der vorgenannten und neuer Evidenz sowie
der Vorgaben der Lungenkrebs-Früherkennungs-Verordnung sorgfältig revidiert hat-
ten [157].
Optimierung von Nutzen, Risiken und

=== Intervention Extract 121 (Dose) ===
n 105
Integration der Tabakentwöhnung
Ein vor kurzem veröffentlichtes Positionspapier zur Implementierung der Tabakent-
wöhnung in ein Lungenkrebs-Screeningprogramm bietet eine ausführliche Zusam-
menfassung der hierzu vorliegenden Evidenz [226]. Rund 35–55% der Teilnehmer in
den randomisierten Low-Dose-CT-Screeningstudien bzw. Pilotstudien waren aktive
Raucher [227], [178], [228]. Ein Rauchstopp senkt ebenso wie ein Niedrigdosis-CT-
Lungenkrebs-Screening-Programm die lungenkrebsbedingte Mortalität. Bereits eine
einmalige therapeutische Intervention zur Tabakentwöhnung ist effektiv und redu-
ziert

=== Intervention Extract 122 (Dose) ===
e in den Survivaldaten. Allerdings zeigte sich nach vier bis fünf Jahren ein kla-
rer, signifikanter Unterschied in der Entdeckung und Diagnose von Zweittumoren.
Diese können dann wieder teilweise kurativ behandelt werden. Vergleichbare Befunde
gibt es auch aus den grossen Screening-Studien mit low-dose CT beim NSCLC Patien-
ten in der Subgruppe mit anamestisch bekannten NSCLC (NLST, NELSON). Lungen-
krebs-specific Survival war in beiden Studien signifikant günstiger in den gescreenten
Randomisationsgruppen. Für die Bildgebung sind damit klare Daten für die Zukunft
bei Patienten mit Lungentumoren

=== Intervention Extract 123 (Dose) ===
kamen zu dem Ergeb-
nis, dass die Nachsorge mit kurzen Zeitintervallen im Vergleich zur rein
Nachs
sorge/
/Verlauf/Follow-Up 483
symptomorientierten Nachsorge keinen Überlebensvorteil erbrachte und nicht kosten-
effektiv war. Diese Daten sind aber im Licht der Screening-Daten mit Rö Thorax und
low-dose CT zu sehen. Viele Patienten mussten randomisiert werden um zu zeigen,
dass der Röntgen-Thorax nicht die relevante Untersuchung für diese Fragestellung
darstellt. Die Screening-Studien konnten dagegen für das Low-dose-CT die signifi-
kante Effektivität dieser Untersuchungsmethode im randomisierten

=== Intervention Extract 124 (Dose) ===
tiv war. Diese Daten sind aber im Licht der Screening-Daten mit Rö Thorax und
low-dose CT zu sehen. Viele Patienten mussten randomisiert werden um zu zeigen,
dass der Röntgen-Thorax nicht die relevante Untersuchung für diese Fragestellung
darstellt. Die Screening-Studien konnten dagegen für das Low-dose-CT die signifi-
kante Effektivität dieser Untersuchungsmethode im randomisierten Vergleich darstel-
len. Das gilt besonders für die besondere Risikogruppe NSCLC mit Vor-Lungenkarzi-
nom
Zum Screening sind bereits die ersten positiven Kosten-Nutzen Analysen durchge-
führt worden (siehe: IQWIG Berich

=== Intervention Extract 125 (Dose) ===
hiede zwischen den einzelnen
Gesundheitssystemen in den betroffenen Ländern zu berücksichtigen.
16 Nachs
sorge/
/Verlauf/Follow-Up 489
Forschungsbedarf
Forschungsbedarf besteht insbesondere hinsichtlich folgender Fragestellungen:
a. Nachsorgeintensität (Methoden), hier besonders Integration des Low-dose CT
nach drei bzw. vier Jahren
b. Nachsorgeintervalle nach lokal-ablativer Therapie (in den ersten drei Jahren)
c. Kosteneffektivität verschiedener Nachsorgestrategien (nach Ausschluss von Unter-
schieden beim 3-J-OS, 5-J-OS, DFS, Qol, Erfassung von Langzeittoxizitäten, jetzt be-
sonders auch bei de

=== Intervention Extract 126 (Dose) ===
d survivin.
Proc.Natl.Acad.Sci.U.S.A. 2006;103:6332-6337. URL:
med/16601104
79. Fox JL, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation
therapy for non-small cell lung cancer. Lung Cancer. 2004;44:287-293. URL:
120. Korte JE, Brennan P, Henley SJ, Boffetta P. Dose-specific meta-analysis and sensitivity analysis
of the relation between alcohol consumption and lung cancer risk. Am.J.Epidemiol.
134. Hong WK, Benner SE, Lippman SM. Evolution of aerodigestive tract 13-cis-retinoid acid chemo-
prevention: the MD Anderson experience Leukemia. Leukemia. 1994;8:S33-S

=== Intervention Extract 127 (Dose) ===
emo-
prevention: the MD Anderson experience Leukemia. Leukemia. 1994;8:S33-S37. URL:
who find it difficult to quit. Eur Respir J. 2015;46(1):61-79. URL:
med.ncbi.nlm.nih.gov/25882805/
148. Piñeiro B, Simmons V, Palmer A, Correa J, Brandon T. Smoking cessation interventions within
the context of Low-Dose Computed Tomography lung cancer screening: A systematic review.
Lung Cancer. 2016;98:91-98. URL:
161. van den Bergh KA, Essink-Bot ML, Borsboom GJ, Scholten ET, van Klaveren RJ, de Koning HJ.
Long-term effects of lung cancer computed tomography screening on health-related quality
of life: the NELSO

=== Intervention Extract 128 (Dose) ===
ted quality
of life: the NELSON trial. Eur Respir J. 2011;38:154-61. URL:
162. van de Wiel JC, Wang Y, Xu DM, van der Zaag-Loonen HJ, van der Jagt EJ, van Klaveren RJ, et
al. Neglectable benefit of searching for incidental findings in the Dutch-Belgian lung cancer
screening trial (NELSON) using low-dose multidetector CT. Eur Radiol. 2007;17:1474-82. URL:
material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol.
268. Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a
screening tool for lung cancer: a meta-analysis. Lung C

